The Wolverine Protocol for dogs
Also searched as: wolverine stack, BPC-157 and TB-500 together
The short answer
BPC-157 combined with TB-500 — the most widely discussed regenerative stack, investigated for soft tissue and orthopaedic injury.
What it is and why these compounds
The Wolverine Protocol pairs BPC-157 with TB-500. The rationale is complementary mechanisms: BPC-157 is investigated for angiogenesis and tendon-to-bone healing, while TB-500 is associated with actin-mediated cell migration and collagen deposition. In the published literature the two are more often studied together than compared against each other, and a canine stifle case report describes their combined use. The practical appeal is that their dosing schedules differ — BPC-157 daily, TB-500 weekly — so the combined burden is lower than two daily injections. The significant caveat is TB-500's cancer contraindication, which governs whether this stack is appropriate at all.
Compounds in this protocol
Before starting
These are the decisions that determine whether this protocol is appropriate at all.
⚠ Read first
TB-500 is contraindicated in dogs with active or suspected cancer. Screening before starting is not optional — it is the single decision that determines whether this protocol is appropriate.
Caution
TB-500 is banned in competitive racing and is detectable in urine and plasma.
Caution
Running two compounds simultaneously makes it substantially harder to attribute any adverse effect to one of them. Staggering the start by a week or two makes attribution possible.
Example timeline
A representative schedule drawn from the published literature, showing what is monitored and when. Any actual protocol should be set by the veterinarian managing the case.
- 1Day 1Screening and baseline
What owners observe
Before the first dose, cancer screening must be complete — this is the gate for TB-500, not an optional extra. Photograph the injury, record how your dog is bearing weight, and note baseline energy and appetite.
Clinical monitoring
Baseline CBC and chemistry panel. Confirm no known or suspected malignancy. Begin BPC-157 daily and TB-500 at loading dose twice weekly.
- 2Week 2Early response
What owners observe
Increased willingness to bear weight is the earliest reliable signal. Mild swelling at TB-500 injection sites is common and settles within a day.
Clinical monitoring
Palpate for reduced swelling and heat. Re-score gait. Verify injection site rotation for both compounds and use separate sites on separate days.
- 3Week 4Transition
What owners observe
Substantial mobility gains are typical. This is the decision point for continuing, tapering, or stopping.
Clinical monitoring
TB-500 moves to maintenance — half dose, once weekly. BPC-157 continues daily. Repeat imaging where applicable may show tissue consolidation.
- 4Week 8Completion
What owners observe
Full return to normal activity with improvement holding steady. Structured rehabilitation matters more at this stage than extending the protocol.
Clinical monitoring
Follow-up imaging to confirm repair. Discontinue TB-500. BPC-157 may continue at a reduced maintenance schedule for chronic conditions under veterinary direction.
Investigated for
Tendon and ligament injury
Strains, partial tears, and chronic tendinopathies in working, sporting, and active dogs.
Cranial cruciate ligament (CCL) tear
Rupture of the stabilising ligament in the stifle, the single most common orthopaedic injury in dogs.
Post-surgical recovery
Supporting tissue repair, comfort, and return to function after an orthopaedic or soft tissue procedure.
Osteoarthritis
Progressive cartilage loss and joint inflammation, affecting a large share of dogs over eight years old.
Common questions
What is the Wolverine Protocol for dogs?+
BPC-157 combined with TB-500 — the most widely discussed regenerative stack, investigated for soft tissue and orthopaedic injury. It combines BPC-157, TB-500.
Is the Wolverine Protocol safe for dogs?+
TB-500 is contraindicated in dogs with active or suspected cancer. Screening before starting is not optional — it is the single decision that determines whether this protocol is appropriate. TB-500 is banned in competitive racing and is detectable in urine and plasma. Running two compounds simultaneously makes it substantially harder to attribute any adverse effect to one of them. Staggering the start by a week or two makes attribution possible.
How long does the Wolverine Protocol run?+
The example timeline runs from day 1 through week 8. Actual duration should be set by the veterinarian managing the case and adjusted on response.
References
- 1.CANINE STUDYHe L, et al. Pharmacokinetics, distribution, metabolism and excretion of BPC 157 in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588722
- 2.CANINE STUDYXu C, et al. Preclinical safety evaluation of body protective compound-157. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. Orthopaedic Journal of Sports Medicine, 2025. PMC12313605
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Jozwiak M, et al. Multifunctionality of BPC 157: Literature and Patent Review. Pharmaceuticals, 2025. PMC11859134
- 6.CANINE STUDYJournal of the American Holistic Veterinary Medical Association Case report: canine stifle injury managed with BPC-157 and TB-500. JAHVM, 2023. View source
- 7.Kleinman HK, Sosne G Thymosin beta 4 promotes dermal healing: animal studies. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 8.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin beta-4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 9.Kwok WH, et al. Doping control analysis of TB-500 in equine urine and plasma. Journal of Chromatography B, 2013. PMID 23084823
- 10.Esposito S, et al. TB500/TB1000: understanding misbranded drugs. Drug Testing and Analysis, 2022. View source
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.